Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA and COMPERA-KIDS)

What this Trial Is About

Researchers are collecting detailed information on patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) who are starting new treatments. The study aims to understand patient characteristics, treatment patterns, clinical outcomes including survival, and how current treatment guidelines are being applied. It includes both adults and children of any age and captures data on different PH forms, including cases linked to congenital heart disease or other conditions. The registry tracks patients receiving newly initiated therapies such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, or prostacyclins, either alone or in combination. Special groups such as patients with PAH associated with congenital heart disease or Eisenmenger physiology are also included. The data collection is ongoing, with follow-up for up to 10 years after enrollment. Participants are documented through an internet-based registry that maintains high data quality using automated checks and monitoring. Researchers evaluate treatment patterns, patient survival, and clinical predictors over time. This observational study does not involve experimental treatments but collects real-world data from routine clinical care to help optimize PAH and PH management. Participation duration varies with follow-up extending up to 10 years after inclusion.

COMPERA / COMPERA-KIDS